FindMyKOL

Mark Scarupa, MD

Basic profile

Institute for Asthma and Allergy

ORCIDNone on fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionWheaton, MD · NortheastSpecialtyAllergy & ImmunologyFocusRheumatology/Immunology
Active KOLEmergingFindMyKOL type: RegionalLatest publication2026Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Mark Scarupa is a Rheumatology/Immunology physician affiliated with Institute for Asthma and Allergy. OpenAlex indexes 35 publications with 326 citations (h-index 8).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
35publications

Publications indexed by OpenAlex. Counts exclude supporting files.

326citations

Citations across these publications.

8h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
42companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

42 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Genentech USA, Inc.
    Program year202542 payments
    $37,261
  • Blueprint Medicines Corporation
    Program year202532 payments
    $33,744
  • GSK
    Program year20257 paymentsResearch
    $22,842
All 138 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Respiratory

    56.3%
    Anti-IgE54.9%
    Omalizumab100%
    Part B, office-administered≥30 patients
    Histamine-1 Receptor Antagonist0.6%
    Azelastine-Fluticasone54%Azelastine Hcl46%
    Part D≥15 patients

    + 2 more classes in this area

  • Anti-infectives

    42.9%
    Human Immunoglobulin G42.7%
    Immune globulin100%
    Part B, office-administered≥16 patients
    Tetracycline-class Drug0.1%
    Doxycycline Hyclate100%
    Part D<11 patients

    + 1 more class in this area

  • Metabolism & gastrointestinal

    0.4%
    Corticosteroid0.4%
    Prednisone100%
    Part D≥30 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”